Brain

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation Surgeons performing complex procedures now…

2 months ago

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation Surgeons performing complex procedures now…

2 months ago

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation Surgeons performing complex procedures now…

2 months ago

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation Surgeons performing complex procedures now…

2 months ago

Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors

MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H…

2 months ago

Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors

MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H…

2 months ago

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque …

2 months ago

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque …

2 months ago

Bioxodes raises €5.5 million Series A extension to continue preparations for pivotal trial of breakthrough stroke candidate

Newton Biocapital enters as new investor, strong participation of existing investorsPivotal Phase 2b trial initiation in 2027 of BIOX-101 to…

2 months ago

Bioxodes raises €5.5 million Series A extension to continue preparations for pivotal trial of breakthrough stroke candidate

Newton Biocapital enters as new investor, strong participation of existing investorsPivotal Phase 2b trial initiation in 2027 of BIOX-101 to…

2 months ago